InsiderTrades

Form 4 for EWTX Edgewise Therapeutics, Inc.

Accepted 2025-08-14 00:00:00 ET · period of report 2025-08-12 · accession 0001562180-25-005794 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-08-14 2025-08-12 EWTX Donovan Joanne M. CMO S - Sale+OE $13.39 -2,862 25.4K -10% -$38.3K
D 2025-08-14 2025-08-12 EWTX Donovan Joanne M. CMO M - OptEx $0.00 +5,781 28.2K +26% $0
DM 2025-08-14 2025-08-12 EWTX Donovan Joanne M. CMO A - Grant $0.00 +196.9K 168.8K New $0
D 2025-08-14 2025-08-12 EWTX Donovan Joanne M. CMO M - OptEx $0.00 -5,781 17.3K -25% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-08-12 S D 2,862 $13.39 25,361 D — — (F2) Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person (F3) The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2 Common Common Stock 2025-08-12 M A 5,781 $0.00 28,223 D — — (F1) Includes 854 shares purchased on May 15, 2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
3 Derivative Restricted Stock Units 2025-08-12 A A 28,125 $0.00 28,125 D $0.00 · — to 2035-08-12 28,125 Common Stock (F5) Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
4 Derivative Stock Option (Right to Buy) 2025-08-12 A A 168,750 $0.00 168,750 D $13.39 · — to 2035-08-12 168,750 Common Stock (F6) 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.
5 Derivative Restricted Stock Units 2025-08-12 M D 5,781 $0.00 17,344 D $0.00 · — to 2034-08-12 5,781 Common Stock (F4) Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.